Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE: Tirabrutinib vs Rituximab and Temozolomide in Relapsed/Refractory PCNSL
NCT07104032Phase 3Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 7
01
Overview
A Phase 3 trial of tirabrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Ono Pharmaceutical. Started Jun 2026; status: recruiting.
02
Drugs
tirabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07104032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104032.